TREM2 Antikörper

Produktnummer ABIN2191861

Dieses Ratte Monoklonal-Antikörper erkennt spezifisch TREM2 in FACS, IP und IA. Er zeigt eine Reaktivität gegenüber Maus und wurde in 1 Publikation erwähnt.

Kurzübersicht für TREM2 Antikörper (ABIN2191861)

Target: TREM2 (Triggering Receptor Expressed On Myeloid Cells 2 (TREM2))

Reaktivität: Maus

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser TREM2 Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), Immunoprecipitation (IP), Immunoassay (IA)

Klon: 6E9

Produktdetails anti-TREM2 Antikörper

Sterilität: 0.2 μm filtered

Anwendungsinformationen

Applikationshinweise: For flow cytometry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS, containing 0.1 % bovine serum albumin and 0.02 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.

Haltbarkeit: 12 months

Referenzen für anti-TREM2 Antikörper (ABIN2191861)

Koga, Inui, Inoue, Kim, Suematsu, Kobayashi, Iwata, Ohnishi, Matozaki, Kodama, Taniguchi, Takayanagi, Takai: "Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis." in: Nature, Vol. 428, Issue 6984, pp. 758-63, (2004) (PubMed).

Details zu TREM2

Target: TREM2 (Triggering Receptor Expressed On Myeloid Cells 2 (TREM2))

Andere Bezeichnung: Triggering Receptor Expressed On Myeloid Cells 2

Hintergrund: The monoclonal antibody 6E9 recognizes mouse membrane-bound as well as soluble triggering receptor expressed on myeloid cells-2 (TREM-2). TREM-2 is a 26 kDa transmembrane glycoprotein that consists of a single extracellular immunoglobulin-like domain, a transmembrane region with a charged lysine residue and a short cytoplasmic tail. It associates with DNAX-activation protein 12 (DAP12) for signaling and function. TREM-2 is expressed on immature monocyte-derived dendritic cells. After activation by microbial products or tumor necrosis factor (TNF) and TNF-related proteins, dendritic cells downregulate the expression of TREM-2. TREM-2 is also expressed by osteoclasts and microglia, where it is involved in bone modeling and brain function, respectively. Another role of TREM-2 might be promoting the removal of apoptotic cells, organic matrix and macromolecules by microglia. Defects in TREM-2 are a cause of polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL), also called presenile dementia with bone cysts or Nasu-Hakola disease (NHD). TREM-2, like TREM-1, can be cleaved on the membrane to release a soluble form of TREM-2 (sTREM-2). Elevated levels of sTREM-2 in CSF of multiple sclerosis patients have been detected. This elevated level may inhibit the anti-inflammatory function of the membrane-bound receptor suggesting sTREM-2 to be a possible target for future therapies. Aliases Triggering receptor expressed on monocytes 2, TREM2 Immunogen Mouse recombinant TREM-2 protein